ES2376225T3 - Genes de elongasa y usos de los mismos. - Google Patents

Genes de elongasa y usos de los mismos. Download PDF

Info

Publication number
ES2376225T3
ES2376225T3 ES03756242T ES03756242T ES2376225T3 ES 2376225 T3 ES2376225 T3 ES 2376225T3 ES 03756242 T ES03756242 T ES 03756242T ES 03756242 T ES03756242 T ES 03756242T ES 2376225 T3 ES2376225 T3 ES 2376225T3
Authority
ES
Spain
Prior art keywords
acid
fatty acids
genes
docosapentaenoic
dgla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03756242T
Other languages
English (en)
Other versions
ES2376225T5 (es
Inventor
Pradip Mukerji
Amanda E. Leonard
Yung-Sheng Huang
Suzette L. Pereira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29709610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2376225(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of ES2376225T3 publication Critical patent/ES2376225T3/es
Publication of ES2376225T5 publication Critical patent/ES2376225T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C12N15/8247—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified lipid metabolism, e.g. seed oil composition
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C12P7/6432—Eicosapentaenoic acids [EPA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C12P7/6434—Docosahexenoic acids [DHA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/86—Products or compounds obtained by genetic engineering
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Birds (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)

Abstract

Una secuencia de nucleótidos aislada o fragmento de la misma que comprende o es complementaria de una secuencia de nucleótidos que codifica un polipéptido que tiene actividad elongasa, en la que el polipéptido elonga ácidos grasos poliinsaturados de cadena de 20 carbonos de longitud y en la que la secuencia de aminoácidos de dicho polipéptido tiene al menos 50 % de identidad con una secuencia de aminoácidos que comprende SEC ID Nº: 121.
ES03756242.8T 2002-05-29 2003-05-29 Genes de elongasa y usos de los mismos Expired - Lifetime ES2376225T5 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US156911 2002-05-29
US10/156,911 US20030163845A1 (en) 1998-09-02 2002-05-29 Elongase genes and uses thereof
PCT/US2003/016863 WO2003102138A2 (en) 2002-05-29 2003-05-29 Elongase genes and uses thereof

Publications (2)

Publication Number Publication Date
ES2376225T3 true ES2376225T3 (es) 2012-03-12
ES2376225T5 ES2376225T5 (es) 2015-01-12

Family

ID=29709610

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03756242.8T Expired - Lifetime ES2376225T5 (es) 2002-05-29 2003-05-29 Genes de elongasa y usos de los mismos

Country Status (10)

Country Link
US (3) US20030163845A1 (es)
EP (1) EP1507855B2 (es)
JP (1) JP4434944B2 (es)
AT (1) ATE538198T1 (es)
AU (1) AU2003243335B2 (es)
BR (1) BR0306655A (es)
CA (1) CA2487095C (es)
ES (1) ES2376225T5 (es)
MX (1) MXPA04011902A (es)
WO (1) WO2003102138A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11952581B2 (en) 2003-08-01 2024-04-09 Basf Plant Science Gmbh Process for the production of polyunsaturated fatty acids in transgenic organisms
EP2169053B1 (de) 2003-08-01 2015-09-09 BASF Plant Science GmbH Verfahren zur Herstellung mehrfach ungesättigter Fettsäuren in transgenen Organismen
US9458436B2 (en) 2004-02-27 2016-10-04 Basf Plant Science Gmbh Method for producing polyunsaturated fatty acids in transgenic plants
EP1720988B1 (de) 2004-02-27 2011-10-12 BASF Plant Science GmbH Verfahren zur herstellung von ungesättigten omega-3-fettsäuren in transgenen organismen
CN102559364B (zh) 2004-04-22 2016-08-17 联邦科学技术研究组织 用重组细胞合成长链多不饱和脂肪酸
BRPI0510132A (pt) 2004-04-22 2007-10-02 Commw Scient Ind Res Org sìntese de ácidos graxos poliinsaturados de cadeia longa por células recombinantes
ES2351973T3 (es) 2004-06-04 2011-02-14 Fluxome Sciences A/S Células metabólicamente modificadas por ingeniería para la producción de ácidos grasos poliinsaturados.
US8092839B2 (en) * 2004-12-13 2012-01-10 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer and other diseases
US8431165B2 (en) * 2004-12-13 2013-04-30 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer and other diseases
JP5181486B2 (ja) * 2006-02-16 2013-04-10 大正製薬株式会社 亜鉛化合物配合経口用組成物
AR059376A1 (es) 2006-02-21 2008-03-26 Basf Plant Science Gmbh Procedimiento para la produccion de acidos grasos poliinsaturados
EP2059588A4 (en) 2006-08-29 2010-07-28 Commw Scient Ind Res Org FATTY ACID SYNTHESIS
CA2687964A1 (en) 2007-06-01 2009-02-19 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
US7892792B2 (en) 2008-06-27 2011-02-22 Indian Institute Of Science Cells expressing Pichia cytochrome C
CN114045301A (zh) 2008-11-18 2022-02-15 联邦科学技术研究组织 产生ω-3脂肪酸的酶和方法
DK2740797T3 (da) * 2011-08-04 2017-02-20 Suntory Holdings Ltd Protein med aktivitet til at fremme fedtsyreforlængelse, derfor kodende gen samt anvendelse deraf
US8816111B2 (en) 2012-06-15 2014-08-26 Commonwealth Scientific And Industrial Research Organisation Lipid comprising polyunsaturated fatty acids
RU2019101182A (ru) * 2013-03-27 2019-03-04 Сантори Холдингз Лимитед Промотор, проявляющий высокую экспрессионную активность в микроорганизмах mortierella
CN104726473B (zh) 2013-12-18 2020-02-14 联邦科学技术研究组织 包含二十二碳六烯酸的提取的植物脂质
CN105219789B (zh) 2014-06-27 2023-04-07 联邦科学技术研究组织 包含二十二碳五烯酸的提取的植物脂质
CN110373436B (zh) 2018-12-11 2022-09-23 山东理工大学 一种产双高-γ-亚麻酸卷枝毛霉细胞工厂的构建方法及发酵技术
CN110923261B (zh) * 2019-12-20 2021-12-17 江南大学 一种提高酿酒酵母细胞膜脂肪酸c20:0和/或c22:0含量的方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420034A (en) * 1986-07-31 1995-05-30 Calgene, Inc. Seed-specific transcriptional regulation
US4943674A (en) * 1987-05-26 1990-07-24 Calgene, Inc. Fruit specific transcriptional factors
GB8507058D0 (en) * 1985-03-19 1985-04-24 Efamol Ltd Pharmaceutical & dietary compositions
GB8524275D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
GB8524276D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
US5188958A (en) * 1986-05-29 1993-02-23 Calgene, Inc. Transformation and foreign gene expression in brassica species
EP0285405A1 (en) 1987-03-31 1988-10-05 Schering Biotech Corporation Glycosylation inhibition factors
GB8714772D0 (en) 1987-06-24 1987-07-29 Efamol Ltd Essential fatty acid compositions
IE63225B1 (en) * 1988-09-13 1995-04-05 Efamol Holdings Use of fatty acids in the treatment of myalgic encephalomyelitis
US5106739A (en) * 1989-04-18 1992-04-21 Calgene, Inc. CaMv 355 enhanced mannopine synthase promoter and method for using same
US5196198A (en) * 1989-06-02 1993-03-23 Abbott Laboratories Parenteral nutrition product
FR2648347B1 (fr) 1989-06-15 1994-04-29 Sederma Sa Preparations cosmetiques possedant des proprietes adoucissantes
US5175095A (en) * 1989-07-19 1992-12-29 Calgene, Inc. Ovary-tissue transcriptional factors
DK0537178T4 (da) * 1990-05-25 2007-07-16 Du Pont Nukleotidsekvens af sojabönne-stearoyl-ACP-desaturase-gen
PH31293A (en) * 1991-10-10 1998-07-06 Rhone Poulenc Agrochimie Production of y-linolenic acid by a delta6-desaturage.
DE69233118T2 (de) 1991-12-04 2004-04-15 E.I. Du Pont De Nemours And Co., Wilmington Fettsäure-desaturase gene aus pflanzen
DE69333025T2 (de) 1992-11-17 2004-04-29 E.I. Du Pont De Nemours And Co., Wilmington Für mikrosom delta 12 fettsäuredesaturase kodierende gene und verwandte enzyme von pflanzen
CA2156720A1 (en) * 1993-02-26 1994-09-01 Jean C. Kridl Geminivirus-based gene expression system
WO1995024488A1 (en) * 1994-03-09 1995-09-14 Abbott Laboratories Transgenic animals producing oligosaccharides and glycoconjugates
US5750176A (en) * 1994-03-09 1998-05-12 Abbott Laboratories Transgenic non-human mammal milk comprising 2'-fucosyl-lactose
EP0749492A1 (en) 1994-03-09 1996-12-27 Abbott Laboratories Humanized milk
US5484724A (en) * 1994-05-26 1996-01-16 Merck & Co., Inc. DNA encoding GLSI
US5545553A (en) * 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US5654402A (en) 1994-10-26 1997-08-05 Michigan State University Methods and compositions relating to plant Δ6 palmitoyl-acyl carrier protein desaturase
WO1998039448A2 (en) 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 186 human secreted proteins
US5972664A (en) 1997-04-11 1999-10-26 Abbott Laboratories Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
US6677145B2 (en) * 1998-09-02 2004-01-13 Abbott Laboratories Elongase genes and uses thereof
US6403349B1 (en) 1998-09-02 2002-06-11 Abbott Laboratories Elongase gene and uses thereof
WO2000070945A2 (en) 1999-05-20 2000-11-30 Karolinska Innovations Ab Fatty acid elongation genes and uses thereof
KR20020073580A (ko) 2000-02-09 2002-09-27 바스프 악티엔게젤샤프트 신규 연장효소 유전자 및 다가불포화 지방산의 제조 방법

Also Published As

Publication number Publication date
US7375205B2 (en) 2008-05-20
US20030163845A1 (en) 2003-08-28
EP1507855B2 (en) 2014-12-03
JP2005527238A (ja) 2005-09-15
EP1507855B1 (en) 2011-12-21
US20050009140A1 (en) 2005-01-13
US7968692B2 (en) 2011-06-28
MXPA04011902A (es) 2005-03-31
CA2487095C (en) 2011-08-16
ES2376225T5 (es) 2015-01-12
ATE538198T1 (de) 2012-01-15
AU2003243335B2 (en) 2008-07-17
BR0306655A (pt) 2005-05-10
JP4434944B2 (ja) 2010-03-17
CA2487095A1 (en) 2003-12-11
WO2003102138A3 (en) 2004-06-17
EP1507855A4 (en) 2006-06-21
AU2003243335A1 (en) 2003-12-19
US20080176944A1 (en) 2008-07-24
EP1507855A2 (en) 2005-02-23
WO2003102138A2 (en) 2003-12-11

Similar Documents

Publication Publication Date Title
MXPA03000750A (es) Genes de elongasa y usos de los mismos.
ES2376225T3 (es) Genes de elongasa y usos de los mismos.
WO2000012720A8 (en) Elongase genes and uses thereof
DE60227951D1 (de) Delta-4-desaturase-gene und ihre verwendung
AR022224A1 (es) Gen de la desaturasa humana y usos del mismo
MXPA03006663A (es) Genes de desaturasa y usos de los mismos.
ATE402944T1 (de) Desaturasegene, von diesen codierte enzyme und verwendungen dafür
EP2392664A3 (en) Production of polyunsaturated fatty acids in oleaginous yeasts
WO2007136671A3 (en) Delta5 desaturase and its use in making polyunsaturated fatty acids
ATE372387T1 (de) Polyungesättigte fettsäuren in pflanzen
WO1999064616A3 (en) Polyunsaturated fatty acids in plants
WO2007136646A3 (en) Delta5 desaturase and its use in making polyunsaturated fatty acids
JP2010540636A5 (es)
ATE542892T1 (de) Delta-17-desaturasen und ihre verwendung bei der herstellung von mehrfach ungesättigten fettsäuren
ATE456645T1 (de) Funktionelle acylglyceride
WO2016040570A3 (en) Dietary emulsion formulations and methods for using the same
MX2015007085A (es) Composiciones de acido omega-3 pentanoico y metodos de uso.
WO2008064096A3 (en) Elongase gene and uses thereof
NO20071180L (no) Delta 6-desaturase-gener og anvendelser derav
AR039898A1 (es) Genes de elongasas y usos de los mismos
Ouyang et al. Resources and bioactivities of polyunsaturated fatty acids
Shen et al. Drosophila lacks C20 and C22 polyunsaturated fatty acids
TH51597B (th) วิธีการที่ถูกปรับปรุงของการรวมกรดไขมันไม่อิ่มตัวหลายตำแหน่งเข้าไว้ในนม